Standout Papers
Citation Impact
Citing Papers
miR-15 and miR-16 induce apoptosis by targeting BCL2
2005 Standout
PARP inhibitors: Synthetic lethality in the clinic
2017 StandoutScience
Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial
2008 Standout
Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial
2007 Standout
Multifunctional doxorubicin loaded superparamagnetic iron oxide nanoparticles for chemotherapy and magnetic resonance imaging in liver cancer
2010
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial
2010 Standout
FoxOs Enforce a Progression Checkpoint to Constrain mTORC1-Activated Renal Tumorigenesis
2010 StandoutNobel
Gastric cancer
2016 Standout
Nanomaterials with enzyme-like characteristics (nanozymes): next-generation artificial enzymes
2013 Standout
Extrahepatic Manifestations of Hepatitis C Infection
2003
Folate receptor-targeted immunotherapy of cancer: mechanism and therapeutic potential
2004
Adjuvant imatinib mesylate after resection of localised, primary gastrointestinal stromal tumour: a randomised, double-blind, placebo-controlled trial
2009 Standout
Testicular Germ-Cell Cancer
1997 Standout
Perioperative Chemotherapy versus Surgery Alone for Resectable Gastroesophageal Cancer
2006 Standout
Induction of anti-VEGF therapy resistance by upregulated expression of microseminoprotein (MSMP)
2017
A view on drug resistance in cancer
2019 StandoutNature
Liver fibrosis
2005 Standout
Natural products: An evolving role in future drug discovery
2011 Standout
Ovarian cancer
2014 Standout
Infection-associated lymphomas derived from marginal zone B cells: a model of antigen-driven lymphoproliferation
2006
Cancer drug resistance: an evolving paradigm
2013 Standout
Population Pharmacokinetics of Pegylated Liposomal CKD‐602 (S‐CKD602) in Patients With Advanced Malignancies
2011
Anthracyclines: Molecular Advances and Pharmacologic Developments in Antitumor Activity and Cardiotoxicity
2004 Standout
Response to antiviral treatment in hepatitis C virus-associated marginal zone lymphomas
2004
Clinical management of gastrointestinal stromal tumors: Before and after STI-571
2002
Clinical applications of quinone-containing alkylating agents
2000
Chemotherapy for advanced gastric cancer
2010
CHOP Chemotherapy plus Rituximab Compared with CHOP Alone in Elderly Patients with Diffuse Large-B-Cell Lymphoma
2002 Standout
Soft-Tissue Sarcomas in Adults
2005 Standout
Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial
2006 Standout
Chemotherapy for advanced gastric cancer
2005
Modeling the Metabolism of Idarubicin to Idarubicinol in Rat Heart: Effect of Rutin and Phenobarbital
2003
Temsirolimus, Interferon Alfa, or Both for Advanced Renal-Cell Carcinoma
2007 Standout
mRNA vaccines for infectious diseases: principles, delivery and clinical translation
2021 StandoutNobel
Long-term results of dose-dense paclitaxel and carboplatin versus conventional paclitaxel and carboplatin for treatment of advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer (JGOG 3016): a randomised, controlled, open-label trial
2013
No Association Between Hepatitis C and B–Cell Lymphoma
1999
Ten years of anti-vascular endothelial growth factor therapy
2016
Cediranib, a pan-VEGFR inhibitor, and olaparib, a PARP inhibitor, in combination therapy for high grade serous ovarian cancer
2016
Peptide-mediated delivery of therapeutic mRNA in ovarian cancer
2019
mAMSA resistant human topoisomerase II mutation G465D has reduced ATP hydrolysis activity
2006
Preparation of 66Ga- and 68Ga-labeled Ga(III)-deferoxamine-folate as potential folate-receptor-targeted PET radiopharmaceuticals
2003
Malignant Gliomas in Adults
2008 Standout
Natural history of HCV infection
2000
Dipeptidyl peptidase 4 is a functional receptor for the emerging human coronavirus-EMC
2013 StandoutNature
Hepatitis C virus infection and non‐hodgkin lymphoma: Results of the NCI‐seer multi‐center case‐control study
2004
Hepatitis C virus in non-Hodgkin's lymphoma. A reappraisal after a prospective case-control study of 300 patients
2000
Gastric cancer
2020 Standout
Radiotherapy plus Concomitant and Adjuvant Temozolomide for Glioblastoma
2005 Standout
Primary brain tumours in adults
2012 Standout
Antiangiogenic therapy in oncology: current status and future directions
2016
Tumor-activated Prodrugs—A New Approach to Cancer Therapy
2004
Exclusion of elderly people from clinical research: a descriptive study of published reports: Table 1
1997
Testicular germ cell tumors and human immunodeficiency virus infection: a report of 26 cases. Italian Cooperative Group on AIDS and Tumors.
1995
Expansion of innate CD5pos B cells expressing high levels of CD81 in hepatitis C virus infected liver
2003
The role of folate receptor α in cancer development, progression and treatment: Cause, consequence or innocent bystander?
2006
VEGF in Signaling and Disease: Beyond Discovery and Development
2019 Standout
External validity of randomised controlled trials: “To whom do the results of this trial apply?”
2005 Standout
Engineered Nanoparticles for Drug Delivery in Cancer Therapy
2014 Standout
Preservation of Fertility in Patients with Cancer
2009 Standout
Pharmacokinetic-Pharmacodynamic Relationships of the Anthracycline Anticancer Drugs
2002
Dipeptidyl-Peptidase IV from Bench to Bedside: An Update on Structural Properties, Functions, and Clinical Aspects of the Enzyme DPP IV
2003
Effect of hepatitis C virus infection on the risk of non‐Hodgkin's lymphoma: A meta‐analysis of epidemiological studies
2004
The Next Generation of Platinum Drugs: Targeted Pt(II) Agents, Nanoparticle Delivery, and Pt(IV) Prodrugs
2016 Standout
Flying Under the Radar: The Immunobiology of Hepatitis C
2006 StandoutNobel
Coordinating Radiometals of Copper, Gallium, Indium, Yttrium, and Zirconium for PET and SPECT Imaging of Disease
2010 Standout
Dual Responsive Enzyme Mimicking Activity of AgX (X = Cl, Br, I) Nanoparticles and Its Application for Cancer Cell Detection
2014
Expression of Apoptosis-Regulating Proteins in Chronic Lymphocytic Leukemia: Correlations With In Vitro and In Vivo Chemoresponses
1998
Antitumor Antibiotics: Bleomycin, Enediynes, and Mitomycin
2005 Standout
Phase II Study of Imatinib in Patients With Recurrent Gliomas of Various Histologies: A European Organisation for Research and Treatment of Cancer Brain Tumor Group Study
2008
Clonal expansion of immunoglobulin M+CD27+ B cells in HCV-associated mixed cryoglobulinemia
2007 StandoutNobel
Clonal B cells in patients with hepatitis C virus–associated mixed cryoglobulinemia contain an expanded anergic CD21low B-cell subset
2011 StandoutNobel
Chemotherapy for advanced gastric cancer
2017 Standout
Carbon nanotubes as multifunctional biological transporters and near-infrared agents for selective cancer cell destruction
2005 Standout
Somatic Hypermutation, Clonal Diversity, and Preferential Expression of the VH 51p1/VL kv325 Immunoglobulin Gene Combination in Hepatitis C Virus–Associated Immunocytomas
1998
Prevalence of Helicobacter pylori and hepatitis C virus infections among non-Hodgkin's lymphoma patients in Southern Switzerland.
2000
Inositol Polyphosphate Multikinase Inhibits Angiogenesis via Inositol Pentakisphosphate-Induced HIF-1α Degradation
2017 StandoutNobel
Nanomaterials with enzyme-like characteristics (nanozymes): next-generation artificial enzymes (II)
2018 Standout
Carbon Nanomaterials for Biological Imaging and Nanomedicinal Therapy
2015 Standout
Randomized Phase II Study of Multiple Dose Levels of CCI-779, a Novel Mammalian Target of Rapamycin Kinase Inhibitor, in Patients With Advanced Refractory Renal Cell Carcinoma
2004
Enzyme-Responsive Snap-Top Covered Silica Nanocontainers
2008 StandoutNobel
Adjuvant Chemotherapy for Adult Soft Tissue Sarcomas of the Extremities and Girdles: Results of the Italian Randomized Cooperative Trial
2001
Somatic Hypermutation, Clonal Diversity, and Preferential Expression of the VH 51p1/VL kv325 Immunoglobulin Gene Combination in Hepatitis C Virus–Associated Immunocytomas
1998
Activation of naïve B lymphocytes via CD81, a pathogenetic mechanism for hepatitis C virus-associated B lymphocyte disorders
2005 StandoutNobel
Folate-mediated delivery of macromolecular anticancer therapeutic agents
2012
Magnetic Nanoparticles: Design and Characterization, Toxicity and Biocompatibility, Pharmaceutical and Biomedical Applications
2012 Standout
The Effects of Nanoparticle Drug Loading on the Pharmacokinetics of Anticancer Agents
2015
Plasma and Cerebrospinal Fluid Population Pharmacokinetics of Temozolomide in Malignant Glioma Patients
2004
Accumulation of B Lymphocytes with a Naive, Resting Phenotype in a Subset of Hepatitis C Patients
2003 StandoutNobel
Cellular uptake of nanoparticles: journey inside the cell
2017 Standout
Dendrimers Designed for Functions: From Physical, Photophysical, and Supramolecular Properties to Applications in Sensing, Catalysis, Molecular Electronics, Photonics, and Nanomedicine
2010 Standout
Application of Pharmacokinetic and Pharmacodynamic Analysis to the Development of Liposomal Formulations for Oncology
2014
Structural Basis of Type II Topoisomerase Inhibition by the Anticancer Drug Etoposide
2011 StandoutScience
What treatment for elderly patients with aggressive lymphoma?
1994
Hepatitis C virus and B-cell non-Hodgkin lymphomas: an Italian multicenter case-control study
2003
Systemic p53 Gene Therapy of Cancer with Immunolipoplexes Targeted by Anti-Transferrin Receptor scFv
2001
High prevalence of hepatitis C virus infection in patients with B‐cell lymphoproliferative disorders in Italy
1997
Fluorescent carbon nanodots conjugated with folic acid for distinguishing folate-receptor-positive cancer cells from normal cells
2012
Interferon in Oncological Practice: Review of Interferon Biology, Clinical Applications, and Toxicities
2001
Multiple Binding Modes of Inhibitors to Carbonic Anhydrases: How to Design Specific Drugs Targeting 15 Different Isoforms?
2012 Standout
Works of Roberto Sorio being referenced
Bevacizumab Combined With Chemotherapy for Platinum-Resistant Recurrent Ovarian Cancer: The AURELIA Open-Label Randomized Phase III Trial
2014 Standout
Phase II study of XR5000 (DACA) administered as a 120-h infusion in patients with recurrent glioblastoma multiforme
2002
Phase II study of XR5000 (DACA), an inhibitor of topoisomerase I and II, administered as a 120-h infusion in patients with advanced ovarian cancer*
2003
A phase II study of sabarubicin (MEN-10755) as second line therapy in patients with locally advanced or metastatic platinum/taxane resistant ovarian cancer
2004
Pharmacokinetics of vinorelbine in patients with liver metastases
1996
Hepatitis C virus and non‐Hodgkin's lymphomas
1996
Population pharmacokinetics and pharmacodynamics of oral etoposide
2001
Entry and evaluation of elderly patients in european organization for research and treatment of cancer (EORTC) new-drug–development studies
1995
Epirubicin and ifosfamide in advanced soft tissue sarcomas
1993
Expression of folate binding protein as a prognostic factor for response to platinum-containing chemotherapy and survival in human ovarian cancer
1998
Evaluation of Two Consecutive Regimens in Advanced Gastric Cancer
1991
Carboplatin and Pegylated Liposomal Doxorubicin for Advanced Ovarian Cancer: Preliminary Activity Results of the MITO-2 Phase III Trial
2008
Hodgkin's disease in patients with HIV infection and in the general population: Comparison of clinicopathological features and survival
1994
The expression of CD26 and CD40 ligand is mutually exclusive in human T- cell non-Hodgkin's lymphomas/leukemias
1995
Mitoxantrone in combination with etoposide and prednimustine in patients older than 70 years with unfavorable non-Hodgkin's lymphoma: a prospective study in 52 patients.
1994
A randomized multicenter phase III study comparing weekly versus every 3 week carboplatin (C) plus paclitaxel (P) in patients with advanced ovarian cancer (AOC): Multicentre Italian Trials in Ovarian Cancer (MITO-7)– European Network of Gynaecological Oncological Trial Groups (ENGOT-ov-10)–Gynecologic Cancer Intergroup (GCIG ) trial.
2013
Phase II Study of Sequential Administration of Docetaxel Followed by Doxorubicin and Cyclophosphamide as First-Line Chemotherapy in Metastatic Breast Cancer
2001
AURELIA: A randomized phase III trial evaluating bevacizumab (BEV) plus chemotherapy (CT) for platinum (PT)-resistant recurrent ovarian cancer (OC).
2012
EO9 phase II study in advanced breast, gastric, pancreatic and colorectal carcinoma by the EORTC Early Clinical Studies Group
1996
Interleukin-2, Interferon-α and Interleukin-2 plus Interferon-α in Renal Cell Carcinoma. A Randomized Phase Ii Trial
1998
Dose-finding and pharmacologic study of chronic oral idarubicin therapy in metastatic breast cancer patients.
2000
Increasing 4'-epidoxorubicin and fixed ifosfamide doses plus granulocyte-macrophage colony-stimulating factor in advanced soft tissue sarcomas: a pilot study.
1997
Pharmacology of chronic oral daily administration of idarubicin.
1998